Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
Be 'active' in the market while NOT being tied to your desk.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals, Inc. | 1.32% | 697.33 | 2.6% | $644.85m | |
| MRNA | Moderna, Inc. | -0.55% | 123.64 | 0.0% | $634.51m | |
| AMGN | Amgen, Inc. | -0.34% | 226.97 | 1.4% | $624.69m | |
| GILD | Gilead Sciences, Inc. | -1.43% | 62.86 | 1.0% | $494.49m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -1.01% | 283.45 | 1.9% | $355.83m | |
| ILMN | Illumina, Inc. | -1.61% | 190.38 | 3.2% | $291.37m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | -5.81% | 4.05 | 0.7% | $283.11m | |
| BIIB | Biogen, Inc. | -1.42% | 197.78 | 1.8% | $184.42m | |
| SAVA | Cassava Sciences, Inc. | -18.00% | 41.87 | 0.0% | $173.71m | |
| BNTX | BioNTech SE | -1.27% | 128.35 | 0.0% | $100.39m | |
| NRBO | NeuroBo Pharmaceuticals, Inc. | -6.44% | 15.54 | 0.0% | $89.03m | |
| NVAX | Novavax, Inc. | -6.42% | 21.00 | 75.6% | $85.66m | |
| BMRN | BioMarin Pharmaceutical, Inc. | -0.09% | 84.84 | 4.2% | $76.07m | |
| EXAS | EXACT Sciences Corp. | -2.74% | 33.41 | 17.6% | $71.49m | |
| CRSP | CRISPR Therapeutics AG | -2.68% | 63.16 | 0.6% | $69.53m |
Company Profile
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.